Medical Care
Global Galectin-3 Inhibitor Market Research Report 2025
- Mar 11, 25
- ID: 77586
- Pages: 79
- Figures: 78
- Views: 17
The global market for Galectin-3 Inhibitor was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Galectin-3 Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Galectin-3 Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Galectin-3 Inhibitor in Diabetes is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Galectin-3 Inhibitor include GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark), Pfizer Inc. (US), Lilly (US), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Galectin-3 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Galectin-3 Inhibitor.
The Galectin-3 Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Galectin-3 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Galectin-3 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlycoMimetics (US)
Galectin Therapeutics Inc (US)
G3 Pharmaceuticals (India)
iTeos (US)
MandalMed, Inc (US)
Angion (US)
Novartis AG (Switzerland)
Galecto Biotech (Denmark)
Pfizer Inc. (US)
Lilly (US)
Segment by Type
Natural
Synthetic
Segment by Application
Diabetes
Heart Failure
Asthma
Rheumatoid Arthritis
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Galectin-3 Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Galectin-3 Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Galectin-3 Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Galectin-3 Inhibitor in Diabetes is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Galectin-3 Inhibitor include GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark), Pfizer Inc. (US), Lilly (US), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Galectin-3 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Galectin-3 Inhibitor.
The Galectin-3 Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Galectin-3 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Galectin-3 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlycoMimetics (US)
Galectin Therapeutics Inc (US)
G3 Pharmaceuticals (India)
iTeos (US)
MandalMed, Inc (US)
Angion (US)
Novartis AG (Switzerland)
Galecto Biotech (Denmark)
Pfizer Inc. (US)
Lilly (US)
Segment by Type
Natural
Synthetic
Segment by Application
Diabetes
Heart Failure
Asthma
Rheumatoid Arthritis
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Galectin-3 Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Galectin-3 Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Natural
1.2.3 Synthetic
1.3 Market by Application
1.3.1 Global Galectin-3 Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Diabetes
1.3.3 Heart Failure
1.3.4 Asthma
1.3.5 Rheumatoid Arthritis
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Galectin-3 Inhibitor Market Perspective (2020-2031)
2.2 Global Galectin-3 Inhibitor Growth Trends by Region
2.2.1 Global Galectin-3 Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Galectin-3 Inhibitor Historic Market Size by Region (2020-2025)
2.2.3 Galectin-3 Inhibitor Forecasted Market Size by Region (2026-2031)
2.3 Galectin-3 Inhibitor Market Dynamics
2.3.1 Galectin-3 Inhibitor Industry Trends
2.3.2 Galectin-3 Inhibitor Market Drivers
2.3.3 Galectin-3 Inhibitor Market Challenges
2.3.4 Galectin-3 Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Galectin-3 Inhibitor Players by Revenue
3.1.1 Global Top Galectin-3 Inhibitor Players by Revenue (2020-2025)
3.1.2 Global Galectin-3 Inhibitor Revenue Market Share by Players (2020-2025)
3.2 Global Galectin-3 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Galectin-3 Inhibitor Revenue
3.4 Global Galectin-3 Inhibitor Market Concentration Ratio
3.4.1 Global Galectin-3 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Galectin-3 Inhibitor Revenue in 2024
3.5 Global Key Players of Galectin-3 Inhibitor Head office and Area Served
3.6 Global Key Players of Galectin-3 Inhibitor, Product and Application
3.7 Global Key Players of Galectin-3 Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Galectin-3 Inhibitor Breakdown Data by Type
4.1 Global Galectin-3 Inhibitor Historic Market Size by Type (2020-2025)
4.2 Global Galectin-3 Inhibitor Forecasted Market Size by Type (2026-2031)
5 Galectin-3 Inhibitor Breakdown Data by Application
5.1 Global Galectin-3 Inhibitor Historic Market Size by Application (2020-2025)
5.2 Global Galectin-3 Inhibitor Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Galectin-3 Inhibitor Market Size (2020-2031)
6.2 North America Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Galectin-3 Inhibitor Market Size by Country (2020-2025)
6.4 North America Galectin-3 Inhibitor Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Galectin-3 Inhibitor Market Size (2020-2031)
7.2 Europe Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Galectin-3 Inhibitor Market Size by Country (2020-2025)
7.4 Europe Galectin-3 Inhibitor Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Galectin-3 Inhibitor Market Size (2020-2031)
8.2 Asia-Pacific Galectin-3 Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2020-2025)
8.4 Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Galectin-3 Inhibitor Market Size (2020-2031)
9.2 Latin America Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Galectin-3 Inhibitor Market Size by Country (2020-2025)
9.4 Latin America Galectin-3 Inhibitor Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Galectin-3 Inhibitor Market Size (2020-2031)
10.2 Middle East & Africa Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2020-2025)
10.4 Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlycoMimetics (US)
11.1.1 GlycoMimetics (US) Company Details
11.1.2 GlycoMimetics (US) Business Overview
11.1.3 GlycoMimetics (US) Galectin-3 Inhibitor Introduction
11.1.4 GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.1.5 GlycoMimetics (US) Recent Development
11.2 Galectin Therapeutics Inc (US)
11.2.1 Galectin Therapeutics Inc (US) Company Details
11.2.2 Galectin Therapeutics Inc (US) Business Overview
11.2.3 Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Introduction
11.2.4 Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.2.5 Galectin Therapeutics Inc (US) Recent Development
11.3 G3 Pharmaceuticals (India)
11.3.1 G3 Pharmaceuticals (India) Company Details
11.3.2 G3 Pharmaceuticals (India) Business Overview
11.3.3 G3 Pharmaceuticals (India) Galectin-3 Inhibitor Introduction
11.3.4 G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.3.5 G3 Pharmaceuticals (India) Recent Development
11.4 iTeos (US)
11.4.1 iTeos (US) Company Details
11.4.2 iTeos (US) Business Overview
11.4.3 iTeos (US) Galectin-3 Inhibitor Introduction
11.4.4 iTeos (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.4.5 iTeos (US) Recent Development
11.5 MandalMed, Inc (US)
11.5.1 MandalMed, Inc (US) Company Details
11.5.2 MandalMed, Inc (US) Business Overview
11.5.3 MandalMed, Inc (US) Galectin-3 Inhibitor Introduction
11.5.4 MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.5.5 MandalMed, Inc (US) Recent Development
11.6 Angion (US)
11.6.1 Angion (US) Company Details
11.6.2 Angion (US) Business Overview
11.6.3 Angion (US) Galectin-3 Inhibitor Introduction
11.6.4 Angion (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.6.5 Angion (US) Recent Development
11.7 Novartis AG (Switzerland)
11.7.1 Novartis AG (Switzerland) Company Details
11.7.2 Novartis AG (Switzerland) Business Overview
11.7.3 Novartis AG (Switzerland) Galectin-3 Inhibitor Introduction
11.7.4 Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.7.5 Novartis AG (Switzerland) Recent Development
11.8 Galecto Biotech (Denmark)
11.8.1 Galecto Biotech (Denmark) Company Details
11.8.2 Galecto Biotech (Denmark) Business Overview
11.8.3 Galecto Biotech (Denmark) Galectin-3 Inhibitor Introduction
11.8.4 Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.8.5 Galecto Biotech (Denmark) Recent Development
11.9 Pfizer Inc. (US)
11.9.1 Pfizer Inc. (US) Company Details
11.9.2 Pfizer Inc. (US) Business Overview
11.9.3 Pfizer Inc. (US) Galectin-3 Inhibitor Introduction
11.9.4 Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.9.5 Pfizer Inc. (US) Recent Development
11.10 Lilly (US)
11.10.1 Lilly (US) Company Details
11.10.2 Lilly (US) Business Overview
11.10.3 Lilly (US) Galectin-3 Inhibitor Introduction
11.10.4 Lilly (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.10.5 Lilly (US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Galectin-3 Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Natural
1.2.3 Synthetic
1.3 Market by Application
1.3.1 Global Galectin-3 Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Diabetes
1.3.3 Heart Failure
1.3.4 Asthma
1.3.5 Rheumatoid Arthritis
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Galectin-3 Inhibitor Market Perspective (2020-2031)
2.2 Global Galectin-3 Inhibitor Growth Trends by Region
2.2.1 Global Galectin-3 Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Galectin-3 Inhibitor Historic Market Size by Region (2020-2025)
2.2.3 Galectin-3 Inhibitor Forecasted Market Size by Region (2026-2031)
2.3 Galectin-3 Inhibitor Market Dynamics
2.3.1 Galectin-3 Inhibitor Industry Trends
2.3.2 Galectin-3 Inhibitor Market Drivers
2.3.3 Galectin-3 Inhibitor Market Challenges
2.3.4 Galectin-3 Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Galectin-3 Inhibitor Players by Revenue
3.1.1 Global Top Galectin-3 Inhibitor Players by Revenue (2020-2025)
3.1.2 Global Galectin-3 Inhibitor Revenue Market Share by Players (2020-2025)
3.2 Global Galectin-3 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Galectin-3 Inhibitor Revenue
3.4 Global Galectin-3 Inhibitor Market Concentration Ratio
3.4.1 Global Galectin-3 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Galectin-3 Inhibitor Revenue in 2024
3.5 Global Key Players of Galectin-3 Inhibitor Head office and Area Served
3.6 Global Key Players of Galectin-3 Inhibitor, Product and Application
3.7 Global Key Players of Galectin-3 Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Galectin-3 Inhibitor Breakdown Data by Type
4.1 Global Galectin-3 Inhibitor Historic Market Size by Type (2020-2025)
4.2 Global Galectin-3 Inhibitor Forecasted Market Size by Type (2026-2031)
5 Galectin-3 Inhibitor Breakdown Data by Application
5.1 Global Galectin-3 Inhibitor Historic Market Size by Application (2020-2025)
5.2 Global Galectin-3 Inhibitor Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Galectin-3 Inhibitor Market Size (2020-2031)
6.2 North America Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Galectin-3 Inhibitor Market Size by Country (2020-2025)
6.4 North America Galectin-3 Inhibitor Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Galectin-3 Inhibitor Market Size (2020-2031)
7.2 Europe Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Galectin-3 Inhibitor Market Size by Country (2020-2025)
7.4 Europe Galectin-3 Inhibitor Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Galectin-3 Inhibitor Market Size (2020-2031)
8.2 Asia-Pacific Galectin-3 Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2020-2025)
8.4 Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Galectin-3 Inhibitor Market Size (2020-2031)
9.2 Latin America Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Galectin-3 Inhibitor Market Size by Country (2020-2025)
9.4 Latin America Galectin-3 Inhibitor Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Galectin-3 Inhibitor Market Size (2020-2031)
10.2 Middle East & Africa Galectin-3 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2020-2025)
10.4 Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlycoMimetics (US)
11.1.1 GlycoMimetics (US) Company Details
11.1.2 GlycoMimetics (US) Business Overview
11.1.3 GlycoMimetics (US) Galectin-3 Inhibitor Introduction
11.1.4 GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.1.5 GlycoMimetics (US) Recent Development
11.2 Galectin Therapeutics Inc (US)
11.2.1 Galectin Therapeutics Inc (US) Company Details
11.2.2 Galectin Therapeutics Inc (US) Business Overview
11.2.3 Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Introduction
11.2.4 Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.2.5 Galectin Therapeutics Inc (US) Recent Development
11.3 G3 Pharmaceuticals (India)
11.3.1 G3 Pharmaceuticals (India) Company Details
11.3.2 G3 Pharmaceuticals (India) Business Overview
11.3.3 G3 Pharmaceuticals (India) Galectin-3 Inhibitor Introduction
11.3.4 G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.3.5 G3 Pharmaceuticals (India) Recent Development
11.4 iTeos (US)
11.4.1 iTeos (US) Company Details
11.4.2 iTeos (US) Business Overview
11.4.3 iTeos (US) Galectin-3 Inhibitor Introduction
11.4.4 iTeos (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.4.5 iTeos (US) Recent Development
11.5 MandalMed, Inc (US)
11.5.1 MandalMed, Inc (US) Company Details
11.5.2 MandalMed, Inc (US) Business Overview
11.5.3 MandalMed, Inc (US) Galectin-3 Inhibitor Introduction
11.5.4 MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.5.5 MandalMed, Inc (US) Recent Development
11.6 Angion (US)
11.6.1 Angion (US) Company Details
11.6.2 Angion (US) Business Overview
11.6.3 Angion (US) Galectin-3 Inhibitor Introduction
11.6.4 Angion (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.6.5 Angion (US) Recent Development
11.7 Novartis AG (Switzerland)
11.7.1 Novartis AG (Switzerland) Company Details
11.7.2 Novartis AG (Switzerland) Business Overview
11.7.3 Novartis AG (Switzerland) Galectin-3 Inhibitor Introduction
11.7.4 Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.7.5 Novartis AG (Switzerland) Recent Development
11.8 Galecto Biotech (Denmark)
11.8.1 Galecto Biotech (Denmark) Company Details
11.8.2 Galecto Biotech (Denmark) Business Overview
11.8.3 Galecto Biotech (Denmark) Galectin-3 Inhibitor Introduction
11.8.4 Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.8.5 Galecto Biotech (Denmark) Recent Development
11.9 Pfizer Inc. (US)
11.9.1 Pfizer Inc. (US) Company Details
11.9.2 Pfizer Inc. (US) Business Overview
11.9.3 Pfizer Inc. (US) Galectin-3 Inhibitor Introduction
11.9.4 Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.9.5 Pfizer Inc. (US) Recent Development
11.10 Lilly (US)
11.10.1 Lilly (US) Company Details
11.10.2 Lilly (US) Business Overview
11.10.3 Lilly (US) Galectin-3 Inhibitor Introduction
11.10.4 Lilly (US) Revenue in Galectin-3 Inhibitor Business (2020-2025)
11.10.5 Lilly (US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Galectin-3 Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Natural
Table 3. Key Players of Synthetic
Table 4. Global Galectin-3 Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Galectin-3 Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Galectin-3 Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Galectin-3 Inhibitor Market Share by Region (2020-2025)
Table 8. Global Galectin-3 Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Galectin-3 Inhibitor Market Share by Region (2026-2031)
Table 10. Galectin-3 Inhibitor Market Trends
Table 11. Galectin-3 Inhibitor Market Drivers
Table 12. Galectin-3 Inhibitor Market Challenges
Table 13. Galectin-3 Inhibitor Market Restraints
Table 14. Global Galectin-3 Inhibitor Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Galectin-3 Inhibitor Market Share by Players (2020-2025)
Table 16. Global Top Galectin-3 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin-3 Inhibitor as of 2024)
Table 17. Ranking of Global Top Galectin-3 Inhibitor Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Galectin-3 Inhibitor Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Galectin-3 Inhibitor, Headquarters and Area Served
Table 20. Global Key Players of Galectin-3 Inhibitor, Product and Application
Table 21. Global Key Players of Galectin-3 Inhibitor, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Galectin-3 Inhibitor Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Galectin-3 Inhibitor Revenue Market Share by Type (2020-2025)
Table 25. Global Galectin-3 Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Galectin-3 Inhibitor Revenue Market Share by Type (2026-2031)
Table 27. Global Galectin-3 Inhibitor Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Galectin-3 Inhibitor Revenue Market Share by Application (2020-2025)
Table 29. Global Galectin-3 Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Galectin-3 Inhibitor Revenue Market Share by Application (2026-2031)
Table 31. North America Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Galectin-3 Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 46. GlycoMimetics (US) Company Details
Table 47. GlycoMimetics (US) Business Overview
Table 48. GlycoMimetics (US) Galectin-3 Inhibitor Product
Table 49. GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 50. GlycoMimetics (US) Recent Development
Table 51. Galectin Therapeutics Inc (US) Company Details
Table 52. Galectin Therapeutics Inc (US) Business Overview
Table 53. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Product
Table 54. Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 55. Galectin Therapeutics Inc (US) Recent Development
Table 56. G3 Pharmaceuticals (India) Company Details
Table 57. G3 Pharmaceuticals (India) Business Overview
Table 58. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Product
Table 59. G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 60. G3 Pharmaceuticals (India) Recent Development
Table 61. iTeos (US) Company Details
Table 62. iTeos (US) Business Overview
Table 63. iTeos (US) Galectin-3 Inhibitor Product
Table 64. iTeos (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 65. iTeos (US) Recent Development
Table 66. MandalMed, Inc (US) Company Details
Table 67. MandalMed, Inc (US) Business Overview
Table 68. MandalMed, Inc (US) Galectin-3 Inhibitor Product
Table 69. MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 70. MandalMed, Inc (US) Recent Development
Table 71. Angion (US) Company Details
Table 72. Angion (US) Business Overview
Table 73. Angion (US) Galectin-3 Inhibitor Product
Table 74. Angion (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 75. Angion (US) Recent Development
Table 76. Novartis AG (Switzerland) Company Details
Table 77. Novartis AG (Switzerland) Business Overview
Table 78. Novartis AG (Switzerland) Galectin-3 Inhibitor Product
Table 79. Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 80. Novartis AG (Switzerland) Recent Development
Table 81. Galecto Biotech (Denmark) Company Details
Table 82. Galecto Biotech (Denmark) Business Overview
Table 83. Galecto Biotech (Denmark) Galectin-3 Inhibitor Product
Table 84. Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 85. Galecto Biotech (Denmark) Recent Development
Table 86. Pfizer Inc. (US) Company Details
Table 87. Pfizer Inc. (US) Business Overview
Table 88. Pfizer Inc. (US) Galectin-3 Inhibitor Product
Table 89. Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 90. Pfizer Inc. (US) Recent Development
Table 91. Lilly (US) Company Details
Table 92. Lilly (US) Business Overview
Table 93. Lilly (US) Galectin-3 Inhibitor Product
Table 94. Lilly (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 95. Lilly (US) Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Galectin-3 Inhibitor Picture
Figure 2. Global Galectin-3 Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Galectin-3 Inhibitor Market Share by Type: 2024 VS 2031
Figure 4. Natural Features
Figure 5. Synthetic Features
Figure 6. Global Galectin-3 Inhibitor Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Galectin-3 Inhibitor Market Share by Application: 2024 VS 2031
Figure 8. Diabetes Case Studies
Figure 9. Heart Failure Case Studies
Figure 10. Asthma Case Studies
Figure 11. Rheumatoid Arthritis Case Studies
Figure 12. Other Case Studies
Figure 13. Galectin-3 Inhibitor Report Years Considered
Figure 14. Global Galectin-3 Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Galectin-3 Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Galectin-3 Inhibitor Market Share by Region: 2024 VS 2031
Figure 17. Global Galectin-3 Inhibitor Market Share by Players in 2024
Figure 18. Global Top Galectin-3 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin-3 Inhibitor as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Galectin-3 Inhibitor Revenue in 2024
Figure 20. North America Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 22. United States Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 26. Germany Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Galectin-3 Inhibitor Market Share by Region (2020-2031)
Figure 34. China Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 42. Mexico Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 46. Turkey Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. GlycoMimetics (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 50. Galectin Therapeutics Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 51. G3 Pharmaceuticals (India) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 52. iTeos (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 53. MandalMed, Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 54. Angion (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 55. Novartis AG (Switzerland) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 56. Galecto Biotech (Denmark) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 57. Pfizer Inc. (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 58. Lilly (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Galectin-3 Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Natural
Table 3. Key Players of Synthetic
Table 4. Global Galectin-3 Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Galectin-3 Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Galectin-3 Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Galectin-3 Inhibitor Market Share by Region (2020-2025)
Table 8. Global Galectin-3 Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Galectin-3 Inhibitor Market Share by Region (2026-2031)
Table 10. Galectin-3 Inhibitor Market Trends
Table 11. Galectin-3 Inhibitor Market Drivers
Table 12. Galectin-3 Inhibitor Market Challenges
Table 13. Galectin-3 Inhibitor Market Restraints
Table 14. Global Galectin-3 Inhibitor Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Galectin-3 Inhibitor Market Share by Players (2020-2025)
Table 16. Global Top Galectin-3 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin-3 Inhibitor as of 2024)
Table 17. Ranking of Global Top Galectin-3 Inhibitor Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Galectin-3 Inhibitor Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Galectin-3 Inhibitor, Headquarters and Area Served
Table 20. Global Key Players of Galectin-3 Inhibitor, Product and Application
Table 21. Global Key Players of Galectin-3 Inhibitor, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Galectin-3 Inhibitor Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Galectin-3 Inhibitor Revenue Market Share by Type (2020-2025)
Table 25. Global Galectin-3 Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Galectin-3 Inhibitor Revenue Market Share by Type (2026-2031)
Table 27. Global Galectin-3 Inhibitor Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Galectin-3 Inhibitor Revenue Market Share by Application (2020-2025)
Table 29. Global Galectin-3 Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Galectin-3 Inhibitor Revenue Market Share by Application (2026-2031)
Table 31. North America Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Galectin-3 Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Galectin-3 Inhibitor Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Galectin-3 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Galectin-3 Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 46. GlycoMimetics (US) Company Details
Table 47. GlycoMimetics (US) Business Overview
Table 48. GlycoMimetics (US) Galectin-3 Inhibitor Product
Table 49. GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 50. GlycoMimetics (US) Recent Development
Table 51. Galectin Therapeutics Inc (US) Company Details
Table 52. Galectin Therapeutics Inc (US) Business Overview
Table 53. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Product
Table 54. Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 55. Galectin Therapeutics Inc (US) Recent Development
Table 56. G3 Pharmaceuticals (India) Company Details
Table 57. G3 Pharmaceuticals (India) Business Overview
Table 58. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Product
Table 59. G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 60. G3 Pharmaceuticals (India) Recent Development
Table 61. iTeos (US) Company Details
Table 62. iTeos (US) Business Overview
Table 63. iTeos (US) Galectin-3 Inhibitor Product
Table 64. iTeos (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 65. iTeos (US) Recent Development
Table 66. MandalMed, Inc (US) Company Details
Table 67. MandalMed, Inc (US) Business Overview
Table 68. MandalMed, Inc (US) Galectin-3 Inhibitor Product
Table 69. MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 70. MandalMed, Inc (US) Recent Development
Table 71. Angion (US) Company Details
Table 72. Angion (US) Business Overview
Table 73. Angion (US) Galectin-3 Inhibitor Product
Table 74. Angion (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 75. Angion (US) Recent Development
Table 76. Novartis AG (Switzerland) Company Details
Table 77. Novartis AG (Switzerland) Business Overview
Table 78. Novartis AG (Switzerland) Galectin-3 Inhibitor Product
Table 79. Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 80. Novartis AG (Switzerland) Recent Development
Table 81. Galecto Biotech (Denmark) Company Details
Table 82. Galecto Biotech (Denmark) Business Overview
Table 83. Galecto Biotech (Denmark) Galectin-3 Inhibitor Product
Table 84. Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 85. Galecto Biotech (Denmark) Recent Development
Table 86. Pfizer Inc. (US) Company Details
Table 87. Pfizer Inc. (US) Business Overview
Table 88. Pfizer Inc. (US) Galectin-3 Inhibitor Product
Table 89. Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 90. Pfizer Inc. (US) Recent Development
Table 91. Lilly (US) Company Details
Table 92. Lilly (US) Business Overview
Table 93. Lilly (US) Galectin-3 Inhibitor Product
Table 94. Lilly (US) Revenue in Galectin-3 Inhibitor Business (2020-2025) & (US$ Million)
Table 95. Lilly (US) Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Galectin-3 Inhibitor Picture
Figure 2. Global Galectin-3 Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Galectin-3 Inhibitor Market Share by Type: 2024 VS 2031
Figure 4. Natural Features
Figure 5. Synthetic Features
Figure 6. Global Galectin-3 Inhibitor Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Galectin-3 Inhibitor Market Share by Application: 2024 VS 2031
Figure 8. Diabetes Case Studies
Figure 9. Heart Failure Case Studies
Figure 10. Asthma Case Studies
Figure 11. Rheumatoid Arthritis Case Studies
Figure 12. Other Case Studies
Figure 13. Galectin-3 Inhibitor Report Years Considered
Figure 14. Global Galectin-3 Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Galectin-3 Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Galectin-3 Inhibitor Market Share by Region: 2024 VS 2031
Figure 17. Global Galectin-3 Inhibitor Market Share by Players in 2024
Figure 18. Global Top Galectin-3 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin-3 Inhibitor as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Galectin-3 Inhibitor Revenue in 2024
Figure 20. North America Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 22. United States Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 26. Germany Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Galectin-3 Inhibitor Market Share by Region (2020-2031)
Figure 34. China Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 42. Mexico Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Galectin-3 Inhibitor Market Share by Country (2020-2031)
Figure 46. Turkey Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Galectin-3 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. GlycoMimetics (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 50. Galectin Therapeutics Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 51. G3 Pharmaceuticals (India) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 52. iTeos (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 53. MandalMed, Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 54. Angion (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 55. Novartis AG (Switzerland) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 56. Galecto Biotech (Denmark) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 57. Pfizer Inc. (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 58. Lilly (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Household Embroidery Machines Market Research Report 2025
Jul 18, 25
Global Residential Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Global Commercial Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232